Ron Dagan, Israel

Poster Author Of 3 e-Posters

 ePoster
Online Abstracts Vaccines - Pneumococcal Vaccines Development C1 Pneumococcal Vaccines Development

SAFETY AND IMMUNOGENICITY OF V114, A 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV), IN ADULTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV): A PHASE 3 TRIAL

Presenter
Authors
Presentation Type
Abstract_Submission
Presentation Topic
C1 Pneumococcal Vaccines Development
Online Abstracts Clinical Sciences - Treatment of Pneumococcal Disease in Infants, Children/Youth, and Adults B5 Treatment of Pneumococcal Disease in Infants, Children/Youth, and Adults

SAFETY AND IMMUNOGENICITY OF V114 ADMINISTERED CONCOMITANTLY WITH INFLUENZA VACCINE (PNEU-FLU)

Presenter
Authors
Presentation Type
Abstract_Submission
Presentation Topic
B5 Treatment of Pneumococcal Disease in Infants, Children/Youth, and Adults
Online Abstracts Basic Sciences - Genomics and Transmission A3 Genomics and Transmission
ePoster not uploaded

GLOBAL GENOMIC EPIDEMIOLOGY OF PNEUMOCOCCAL SEROTYPE 2 ISOLATED DURING 1989 TO 2019

Presenter
Authors
Presentation Type
Abstract_Submission
Presentation Topic
A3 Genomics and Transmission

Author Of 6 Presentations

 Conference Calendar

EMERGENCE OF A COTRIMOXAZOLE RESISTANT SEROTYPE 16F LINEAGE IN AN INTENSIVELY VACCINATED AFRICAN BIRTH COHORT: THE DRAKENSTEIN CHILD HEALTH STUDY (ID 930)

Session Name
Basic Sciences - Conventional and Molecular Microbiology
Presenter
Authors

GLOBAL GENOMIC EPIDEMIOLOGY OF PNEUMOCOCCAL SEROTYPE 2 ISOLATED DURING 1989 TO 2019 (ID 1084)

Session Name
Basic Sciences - Genomics and Transmission
Presenter
Authors

Abstract

Background

Serotype 2 was a major cause of pneumococcal pneumonia about 100 years ago and then disappeared. Recently, serotype 2 re-emerged in many countries, including Bangladesh and associated with meningitis. This study aims to understand genomic and epidemiological characteristics of newly emerged serotype 2 strains.

Methods

Whole-genome sequencing was performed on 146 isolates (invasive= 125, carriage= 8 and other= 5, unknown= 8) collected between 1989 and 2017. Data were analyzed for comparative genomics, antimicrobial resistance and molecular typing.

Results

Isolates were from 16 countries, mostly in Asia (n=93), Africa (n=23) and Oceania (n=26). Bangladesh (n=66) and Papua New Guinea (n=26) contributed 63% of the isolates. Among the known clinical conditions, 80% (91/113) were from meningitis. All isolates belonged to GPSC96 lineage and descended from two predominant sequence types: ST74 found in Asia and Africa, and ST1504 found in Papua New Guinea and Israel. Almost all isolates were sensitive to all antibiotics. No significant genetic differences were detected between invasive and carriage isolates.

Conclusions

Our findings don’t explain why the recent increase in serotype 2 occurred but exclude an outbreak or emergence of an antimicrobial-resistant strain as the cause. These isolates have unusually high propensity to be invasive, mostly causing meningitis.

Hide

SAFETY AND IMMUNOGENICITY OF V114 ADMINISTERED CONCOMITANTLY WITH INFLUENZA VACCINE (PNEU-FLU) (ID 619)

Session Name
Clinical Sciences - Treatment of Pneumococcal Disease in Infants, Children/Youth, and Adults
Presenter
Authors

Abstract

Background

Streptococcus pneumoniae and influenza virus are significant causes of disease worldwide. V114, an investigational 15-valent PCV, contains all serotypes in PCV13 plus serotypes 22F and 33F. This phase 3 trial evaluated safety and immunogenicity of concomitant and non-concomitant administration of V114 and quadrivalent influenza vaccine (QIV) in adults aged ≥50 years.

Methods

Overall, 1200 participants were randomized 1:1 to receive either V114 administered concomitantly with QIV (concomitant group) or V114 administered 1 month after QIV (non-concomitant group); randomization was stratified by age and history of prior pneumococcal polysaccharide vaccine. Pneumococcal serotype-specific opsonophagocytic activity (OPA) and influenza strain-specific hemagglutination inhibition (HAI) antibodies were measured prior and 30 days postvaccination. Demonstration of non-inferior immunogenicity between the concomitant and non-concomitant group required the lower bound of the 95% confidence interval of the ratio of OPA and HAI geometric mean titers (GMTs) to be ≥0.5.

Results

Proportions of participants reporting any AE, injection-site AEs, and systemic AEs were generally comparable between vaccination groups. Non-inferiority was demonstrated for all 15 pneumococcal serotypes and all 4 influenza strains between vaccination groups.

Conclusions

V114 administered concomitantly with QIV was generally well tolerated and immunologically non-inferior to non-concomitant administration, supporting co-administration of both vaccines.

Hide

SAFETY AND IMMUNOGENICITY OF V114, A 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV), IN ADULTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV): A PHASE 3 TRIAL (ID 985)

Session Name
Vaccines - Pneumococcal Vaccines Development
Presenter
Authors

Abstract

Background

HIV infection increases the risk of pneumococcal disease (PD). Sequential vaccination with pneumococcal conjugate vaccine (PCV) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for prevention of PD. V114, an investigational 15-valent PCV, contains all serotypes in PCV13 plus serotypes 22F and 33F. This phase 3 trial evaluated immunogenicity and safety of V114 or PCV13 followed 8 weeks later by PPSV23 in HIV-infected adults.

Methods

Eligible HIV-infected adults aged ≥18 years, pneumococcal vaccine naïve and receiving antiretroviral therapy were randomized 1:1 to receive either V114 or PCV13 followed by PPSV23. Randomization was stratified by CD4 cell count. Serotype-specific opsonophagocytic activity (OPA) and immunoglobulin G (IgG) antibodies were measured immediately prior and 30 days after each vaccination.

Results

Enrollment of study participants has been completed. Safety outcomes and serotype-specific OPA geometric mean titers and IgG geometric mean concentrations following vaccination with V114 or PCV13 will be summarized by vaccination group (primary). Sub-group analysis will include CD4 strata if there are more than 10 participants per group. Summaries of safety and immunogenicity outcomes following PPV23 will also be provided.

Conclusions

Findings will demonstrate whether immunization with V114 or PCV13 followed by PPSV23 is well-tolerated and immunogenic in HIV-infected adults.

Hide

REDUCTION IN PNEUMOCOCCAL NASOPHARYNGEAL CARRIAGE WITH THREE DIFFERENT SCHEDULES OF PNEUMOCOCCAL CONJUGATE VACCINES IN INFANCY (ID 1193)

Session Name
Vaccines - Impact of Vaccine programs and Serotype Replacement
Presenter
Authors

SEROTYPE PATTERNS DIFFER IN CARRIAGE IN CHILDREN <24 MONTHS VS 24-59 MONTHS OF AGE (ID 320)

Session Name
Population Sciences - Epidemiology, Economics, and Mathematical Modelling
Presenter
Authors